AR106948A1 - Agonistas del receptor de apelina y método de uso - Google Patents

Agonistas del receptor de apelina y método de uso

Info

Publication number
AR106948A1
AR106948A1 ARP160103719A ARP160103719A AR106948A1 AR 106948 A1 AR106948 A1 AR 106948A1 AR P160103719 A ARP160103719 A AR P160103719A AR P160103719 A ARP160103719 A AR P160103719A AR 106948 A1 AR106948 A1 AR 106948A1
Authority
AR
Argentina
Prior art keywords
substituted
independently selected
alkyl
heterocyclyl
nrara
Prior art date
Application number
ARP160103719A
Other languages
English (en)
Inventor
C Myers Michael
Michael Lawrence R
Finlay Heather
J Chao Hannguang
Meng Wei
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR106948A1 publication Critical patent/AR106948A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto caracterizado por la fórmula (1), o un estereoisómero, un enantiómero, un diastereoisómero, un tautómero o una sal de aquel aceptable desde el punto de vista farmacéutico, en donde: alk es C₁₋₆ alquilo sustituido con 1 - 5 R⁴; el anillo A se selecciona independientemente de arilo y heteroarilo de 5 ó 6 miembros que comprenden átomos de carbono y 1 - 4 heteroátomos seleccionados de N, NR³ᵃ, O y S, cada uno sustituido con 1 - 4 R³; el anillo B se selecciona independientemente de arilo, heteroarilo y cicloalquilo, cada uno sustituido con 1 - 4 R¹; R¹ se selecciona independientemente de H, halógeno, NO₂, -(CH₂)ₙORᵇ, (CH₂)ₙS(O)ₚRᶜ, -(CH₂)ₙC(=O)Rᵇ, -(CH₂)ₙNRᵃRᵃ, -(CH₂)ₙCN, -(CH₂)ₙC(=O)NRᵃRᵃ, -(CH₂)ₙNRᵃC(=O)Rᵇ, -(CH₂)ₙNRᵃC(=O)NRᵃRᵃ, -(CH₂)ₙNRᵃC(=O)ORᵇ, -(CH₂)ₙOC(=O)NRᵃRᵃ, -(CH₂)ₙC(=O)ORᵇ, -(CH₂)ₙS(O)ₚNRᵃRᵃ, -(CH₂)ₙNRᵃS(O)ₚNRᵃRᵃ, -(CH₂)ₙNRᵃS(O)ₚRᶜ, C₁₋₄ alquilo sustituido con 0 - 3 Rᵉ, -(CH₂)ₙ-C₃₋₆ carbociclilo sustituido con 0 - 3 Rᵉ y -(CH₂)ₙ-heterociclilo sustituido con 0 - 3 Rᵉ; R² se selecciona independientemente de C₂₋₅ alquilo sustituido con 0 - 3 Rᵉ; C₂₋₅ alquenilo sustituido con 1 - 3 Rᵉ, arilo sustituido con 0 - 3 Rᵉ, heterociclilo sustituido con 0 - 3 Rᵉ y C₃₋₆ cicloalquilo sustituido con 0 - 3 Rᵉ; siempre que, cuando R² es C₂₋₅ alquilo, y el átomo de carbono y los grupos unidos a este, salvo el que está unido al anillo de pirimidina, se puedan reemplazar por O, N y S; R³ se selecciona independientemente de H, halógeno, -(CH₂)ₙORᵇ, -(CH₂)ₙS(O)ₚRᶜ, -(CH₂)ₙC(=O)Rᵇ, -(CH₂)ₙNRᵃRᵃ, -(CH₂)ₙCN, -(CH₂)ₙC(=O)NRᵃRᵃ, -(CH₂)ₙNRᵃC(=O)Rᵇ, -(CH₂)ₙNRᵃC(=O)NRᵃRᵃ, -(CH₂)ₙNRᵃC(=O)ORᵇ, -(CH₂)ₙOC(=O)NRᵃRᵃ, -(CH₂)ₙC(=O)ORᵇ, -(CH₂)ₙS(O)ₚNRᵃRᵃ, -(CH₂)ₙNRᵃS(O)ₚNRᵃRᵃ, -(CH₂)ₙNRᵃS(O)ₚRᶜ, C₁₋₅ alquilo sustituido con 0 - 3 Rᵉ, (CH₂)ₙ-C₃₋₆ carbociclilo sustituido con 0 - 3 Rᵉ y -(CH₂)ₙ-heterociclilo que comprende átomos de carbono y 1 - 4 heteroátomos seleccionados de N, NR³ᵃ, O, S y sustituidos con 0 - 3 Rᵉ; R³ᵃ se selecciona independientemente de H, -S(O)ₚRᶜ, -C(=O)Rᵇ, -C(=O)NRᵃRᵃ, -C(=O)ORᵇ, -S(O)ₚNRᵃRᵃ, C₁₋₅ alquilo sustituido con 0 - 3 Rᵉ, -(CH₂)ₙ-C₃₋₆ carbociclilo sustituido con 0 - 3 Rᵉ y -(CH₂)ₙ-heterociclilo sustituido con 0 - 3 Rᵉ; R⁴ se selecciona independientemente de C₁₋₅ alquilo sustituido con 0 - 3 Rᵉ, (CH₂)ₙ-C₃₋₆ carbociclilo sustituido con 0 - 3 Rᵉ y -(CH₂)ₙ-heterociclilo sustituido con 0 - 3 Rᵉ; Rᵃ, en cada caso, se selecciona independientemente de H, C₁₋₆ alquilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquenilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquinilo sustituido con 0 - 5 Rᵉ, -(CH₂)ₙ-C₃₋₁₀ carbociclilo sustituido con 0 - 5 Rᵉ y -(CH₂)ₙ-heterociclilo sustituido con 0 - 5 Rᵉ; o Rᵃ y Rᵃ, junto con el átomo de nitrógeno al que están unidos, forman un anillo heterocíclico sustituido con 0 - 5 Rᵉ; Rᵇ, en cada caso, se selecciona independientemente de H, C₁₋₆ alquilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquenilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquinilo sustituido con 0 - 5 Rᵉ, -(CH₂)ₙ-C₃₋₁₀ carbociclilo sustituido con 0 - 5 Rᵉ y -(CH₂)ₙ-heterociclilo sustituido con 0 - 5 Rᵉ; Rᶜ, en cada caso, se selecciona independientemente de C₁₋₆ alquilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquenilo sustituido con 0 - 5 Rᵉ, C₂₋₆ alquinilo sustituido con 0 - 5 Rᵉ, C₃₋₆ carbociclilo y heterociclilo; Rᵈ, en cada caso, se selecciona independientemente de H y C₁₋₆ alquilo sustituido con 0 - 5 Rᵉ; Rᵉ, en cada caso, se selecciona independientemente de C₁₋₆, alquilo (opcionalmente sustituido con halógeno, OH y CN), C₂₋₆, alquenilo, C₂₋₆ alquinilo, -(CH₂)ₙ-C₃₋₆ cicloalquilo, -(CH₂)ₙ-C₄₋₆ heterociclilo, -(CH₂)ₙ-arilo, -(CH₂)ₙ-heteroarilo, F, Cl, Br, CN, NO₂, =O, CO₂H, -(CH₂)ₙORᶠ, S(O)ₚRᶠ, C(=O)NRᶠRᶠ, NRᶠC(=O)Rᶠ, S(O)ₚNRᶠRᶠ, NRᶠS(O)ₚRᶠ, NRᶠC(=O)ORᶠ, OC(=O)NRᶠRᶠ y -(CH₂)ₙNRᶠRᶠ; Rᶠ, en cada caso, se selecciona, independientemente de H, C₁₋₅ alquilo (opcionalmente sustituido con halógeno y OH), C₃₋₆ cicloalquilo y fenilo, o Rᶠ y Rᶠ, junto con el átomo de nitrógeno al que están unidos, forman un anillo heterocíclico opcionalmente sustituido con C₁₋₄ alquilo; n se selecciona independientemente de 0, 1, 2 y 3; y p, en cada caso, se selecciona independientemente de 0, 1 y 2.
ARP160103719A 2015-12-04 2016-12-02 Agonistas del receptor de apelina y método de uso AR106948A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562263106P 2015-12-04 2015-12-04

Publications (1)

Publication Number Publication Date
AR106948A1 true AR106948A1 (es) 2018-03-07

Family

ID=57570463

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP160103719A AR106948A1 (es) 2015-12-04 2016-12-02 Agonistas del receptor de apelina y método de uso

Country Status (20)

Country Link
US (2) US11390616B2 (es)
EP (1) EP3383860B1 (es)
JP (1) JP6817305B2 (es)
KR (1) KR102678264B1 (es)
CN (1) CN108473466B (es)
AR (1) AR106948A1 (es)
AU (1) AU2016365340B2 (es)
BR (1) BR112018010720A8 (es)
CA (1) CA3007280A1 (es)
CL (1) CL2018001478A1 (es)
CO (1) CO2018006662A2 (es)
EA (1) EA037257B1 (es)
ES (1) ES2858312T3 (es)
HK (1) HK1255162A1 (es)
IL (1) IL259660B (es)
MX (1) MX2018006217A (es)
PE (1) PE20181269A1 (es)
TW (1) TW201722920A (es)
UY (1) UY37005A (es)
WO (1) WO2017096130A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2545964A1 (en) 2011-07-13 2013-01-16 Phenex Pharmaceuticals AG Novel FXR (NR1H4) binding and activity modulating compounds
SI3300500T1 (sl) 2015-05-20 2020-07-31 Amgen Inc. Triazolni agonisti receptorja APJ
ES2739526T3 (es) 2015-06-03 2020-01-31 Bristol Myers Squibb Co Agonistas de APJ de 4-hidroxi-3-(heteroaril)piridin-2-ona para su uso en el tratamiento de trastornos cardiovaculares
CA3001974A1 (en) 2015-10-14 2017-04-20 Bristol-Myers Squibb Company 2,4-dihydroxy-nicotinamides as apj agonists
JP6948322B2 (ja) 2015-12-16 2021-10-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ａｐｊ受容体のａｐｊアゴニストとしてのヘテロアリールヒドロキシピリミジノン
AU2017238504B2 (en) 2016-03-24 2021-05-27 Bristol-Myers Squibb Company 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists
US9988369B2 (en) 2016-05-03 2018-06-05 Amgen Inc. Heterocyclic triazole compounds as agonists of the APJ receptor
CA2968836A1 (en) 2016-06-13 2017-12-13 Gilead Sciences, Inc. Fxr (nr1h4) modulating compounds
MX2018015443A (es) 2016-06-13 2019-04-11 Gilead Sciences Inc Compuestos moduladores de fxr (nr1h4).
KR102521955B1 (ko) 2016-06-14 2023-04-13 브리스톨-마이어스 스큅 컴퍼니 Apj 수용체 효능제로서의 4-히드록시-3-술포닐피리딘-2(1h)-온
WO2017218633A1 (en) * 2016-06-14 2017-12-21 Bristol-Myers Squibb Company 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-one as apj agonists
EP3526198B1 (en) 2016-10-14 2020-08-12 Bristol-Myers Squibb Company 3-sulfonyl-5-aminopyridine-2,4-diol apj agonists
EP3541805B1 (en) 2016-11-16 2020-10-14 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
EP3541810B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
EP3541804A1 (en) 2016-11-16 2019-09-25 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
EP3541803B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole pyridyl compounds as agonists of the apj receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
JP6906626B2 (ja) 2017-03-28 2021-07-21 ギリアード サイエンシーズ， インコーポレイテッド 肝疾患を処置するための治療的組み合わせ
EP3704122B1 (en) 2017-11-03 2021-09-01 Amgen Inc. Fused triazole agonists of the apj receptor
CN112055713A (zh) * 2018-03-01 2020-12-08 安娜普尔纳生物股份有限公司 用于治疗与apj受体活性有关的疾病的化合物和组合物
WO2019213006A1 (en) * 2018-05-01 2019-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
BR112021011762A2 (pt) 2019-01-15 2021-11-03 Gilead Sciences Inc Compostos para modulação de fxr (nr1h4)
AU2020225225B2 (en) 2019-02-19 2022-12-22 Gilead Sciences, Inc. Solid forms of FXR agonists

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2263639A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
DE4425616A1 (de) * 1994-07-20 1996-01-25 Basf Ag Hydroxypyridoncarbonsäureamide, deren Herstellung und Verwendung
JPH08325248A (ja) 1995-05-26 1996-12-10 Chugoku Kayaku Kk テトラゾール類の新規な合成試薬及びそれを用いたテトラゾール類の製造方法
AU744518B2 (en) 1996-07-01 2002-02-28 Dr. Reddy's Laboratories Limited Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
DE69828445D1 (de) 1998-04-23 2005-02-03 Reddys Lab Ltd Dr Heterozyklische verbindungen,und deren verwendung in arzneimittel,verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammenstellungen
EP1301490A2 (en) 2000-07-18 2003-04-16 Neurogen Corporation 5-substituted 2-aryl-4-pyrimidinones
CA2477008A1 (en) 2002-02-22 2003-09-04 Pharmacia & Upjohn Company Substituted pyrimidinones and pyrimidinthiones
BRPI0409649A (pt) 2003-04-23 2006-04-25 Pharmacia & Upjohn Co Llc pirimidinonas e pirimidinotionas substituìdas como antagonistas de crf
JP2007505121A (ja) 2003-09-08 2007-03-08 武田薬品工業株式会社 ジペプチジルぺプチダーゼ阻害剤
CA2547209A1 (en) 2003-12-19 2005-07-07 Merck & Co., Inc. Mitotic kinesin inhibitors
US7973060B2 (en) 2005-10-13 2011-07-05 Crystalgenomics, Inc. Fab I inhibitor and process for preparing same
CA2630884A1 (en) 2005-11-30 2007-06-07 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
EP1903052A3 (en) * 2006-07-28 2008-04-02 Faust Pharmaceuticals SA APJ receptor ligands and uses thereof
CN103140221A (zh) 2010-08-10 2013-06-05 盐野义制药株式会社 新型杂环衍生物和含有其的药物组合物
US20140005181A1 (en) * 2012-06-21 2014-01-02 Sanford-Burnham Medical Research Institute Small molecule antagonists of the apelin receptor for the treatment of disease
WO2014031928A2 (en) 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
MX2015003653A (es) 2012-09-21 2015-09-25 Sanofi Sa Derivados de amida del acido benzoimidazol-carboxilico como moduladores del receptor apj.
ES2739526T3 (es) 2015-06-03 2020-01-31 Bristol Myers Squibb Co Agonistas de APJ de 4-hidroxi-3-(heteroaril)piridin-2-ona para su uso en el tratamiento de trastornos cardiovaculares
CA3001974A1 (en) 2015-10-14 2017-04-20 Bristol-Myers Squibb Company 2,4-dihydroxy-nicotinamides as apj agonists
JP6948322B2 (ja) 2015-12-16 2021-10-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ａｐｊ受容体のａｐｊアゴニストとしてのヘテロアリールヒドロキシピリミジノン
AU2017238504B2 (en) 2016-03-24 2021-05-27 Bristol-Myers Squibb Company 6-hydroxy-4-oxo-1,4-dihydropyrimidine-5-carboxamides as APJ agonists
WO2017218633A1 (en) 2016-06-14 2017-12-21 Bristol-Myers Squibb Company 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-one as apj agonists
KR102521955B1 (ko) 2016-06-14 2023-04-13 브리스톨-마이어스 스큅 컴퍼니 Apj 수용체 효능제로서의 4-히드록시-3-술포닐피리딘-2(1h)-온
EP3526198B1 (en) 2016-10-14 2020-08-12 Bristol-Myers Squibb Company 3-sulfonyl-5-aminopyridine-2,4-diol apj agonists

Also Published As

Publication number Publication date
KR102678264B1 (ko) 2024-06-24
US20220315569A1 (en) 2022-10-06
PE20181269A1 (es) 2018-08-03
JP6817305B2 (ja) 2021-01-20
KR20180086251A (ko) 2018-07-30
EP3383860B1 (en) 2021-01-20
IL259660B (en) 2021-01-31
BR112018010720A2 (pt) 2018-11-21
AU2016365340B2 (en) 2021-05-27
AU2016365340A1 (en) 2018-07-19
WO2017096130A1 (en) 2017-06-08
CO2018006662A2 (es) 2018-07-10
EA037257B1 (ru) 2021-02-26
CA3007280A1 (en) 2017-06-08
MX2018006217A (es) 2018-08-01
TW201722920A (zh) 2017-07-01
IL259660A (en) 2018-07-31
US20210198246A1 (en) 2021-07-01
EP3383860A1 (en) 2018-10-10
US11390616B2 (en) 2022-07-19
JP2018535999A (ja) 2018-12-06
CL2018001478A1 (es) 2018-09-14
EA201891344A1 (ru) 2018-12-28
CN108473466B (zh) 2022-04-19
CN108473466A (zh) 2018-08-31
HK1255162A1 (zh) 2019-08-09
BR112018010720A8 (pt) 2019-02-26
ES2858312T3 (es) 2021-09-30
UY37005A (es) 2017-06-30

Similar Documents

Publication Publication Date Title
AR106948A1 (es) Agonistas del receptor de apelina y método de uso
AR107061A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apj
AR104884A1 (es) Compuestos de 4-hidroxi-3-(heteroaril)piridin-2-ona como agonistas de apj
AR107973A1 (es) 6-hidroxi-4-oxo-1,4-dihidropirimidin-5-carboxamidas como agonista de apj
AR098414A1 (es) PIPERAZINAS DE PIRAZOLO SUSTITUIDO COMO INHIBIDORES DE CASEÍNA QUINASA 1 d/e
AR108838A1 (es) Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa
AR099379A1 (es) Compuestos tricíclicos como agentes antineoplásicos
AR103064A1 (es) Compuestos moduladores de fxr (nr1h4)
AR105238A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
AR105845A1 (es) Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4
AR104176A1 (es) Inhibidores de ido (indolamina-2,3-dioxigenasa)
AR110405A1 (es) Compuestos
AR096788A1 (es) Compuestos tricíclicos de carboxamida como inhibidores potentes de rock
AR113688A1 (es) Proceso para la preparación de compuestos de piridiminio ópticamente activo
AR117617A1 (es) Compuestos de sulfonilurea como inhibidores de la actividad de interleuquina 1
AR092349A1 (es) Imidazotriazincarbonitrilos utiles como inhibidores de quinasa
AR094929A1 (es) Derivados de fenilpirazol como inhibidores potentes de rock1 y rock2
AR094299A1 (es) Derivados de ftalazin-1(2h)-ona sustituidos
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
AR103232A1 (es) ANTAGONISTAS DE TGFbR
AR100327A1 (es) Inhibidores de quinasa relacionados con tropomiosina
AR099495A1 (es) Derivados de amida, antagonistas de orexina
AR090557A1 (es) DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
AR101589A1 (es) Derivados de iminonitrilo
AR105929A1 (es) Derivados de 2-difluorometil-nicotin(tio)carboxanilida sustituidos y su uso como fungicidas

Legal Events

Date Code Title Description
FB Suspension of granting procedure